Thirona, founded in 2014 and headquartered in The Netherlands, is at the forefront of innovation in the Analytics and Health Care industries. The company specializes in AI-powered lung image analysis, offering advanced tools for thoracic imaging through its LungQ® portfolio.
Thirona's technology stands out due to its robust segmentation capabilities, providing precise quantification of bronchial, parenchymal, and vascular lung structures. The efficacy and reliability of these solutions are backed by over 200 peer-reviewed publications, attesting to their reproducibility across varied populations and disease severities.
The company collaborates with acclaimed research institutes, academic hospitals, pharmaceutical innovators, and MedTech partners. Presently, LungQ® is operational in over 1,200 hospitals worldwide. Thirona's commitment to advancing precision medicine is reinforced by a recent €5.00M Series B investment on 01 September 2023, led by Borski Fund and HERAN Partners, enabling further growth and innovation.